News Appili Therapeutics Inc.

Equities

APLI

CA03783R1073

Market Closed - Toronto S.E. Other stock markets 01:06:12 2024-04-19 pm EDT			5-day change	1st Jan Change
0.04 ^CAD	+14.29%		-11.11%	+14.29%

Apr. 02	Appili Therapeutics To be Acquired by Aditxt, Inc.	MT
Apr. 02	Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. for $6.7 million.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Appili Therapeutics Signs Definitive Agreement to be acquired by Aditxt, Inc.	Apr. 03	AQ
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense	Apr. 03	AQ
Appili Therapeutics To be Acquired by Aditxt, Inc.	Apr. 02	MT
Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. for $6.7 million.	Apr. 01	CI
Appili Therapeutics Notes Researchers Publish Manuscript on Prevention and Emergency Response to Tularemia Outbreaks	Mar. 12	MT
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks	Mar. 12	AQ
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024	Feb. 13	AQ
Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan	Dec. 18	AQ
Appili Therapeutics Says Patent Issued For Biodefence Vaccine Candidate ATI-1701, Provides Update on Bridge Loan	Dec. 15	MT
Appili Therapeutics Brief: Announcing Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Providing Update on Bridge Loan	Dec. 15	MT
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan	Dec. 15	BU
Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 14	CI
Appili Therapeutics Inc. Appoints Prakash Gowd to its Board of Directors	Nov. 13	CI
Appili Therapeutics Q2 Net Loss and Comprehensive Loss Narrows Vs a Year Ago	Nov. 13	MT
Appili Therapeutics Brief: As of September 30, 2023, Co had cash of $0.4 million, compared to $2.5 million on March 31, 2023.	Nov. 13	MT
Appili Therapeutics Brief: Net loss and comprehensive loss of $1.0 million or $0.01 loss per share for the Three months ended September 30, 2023	Nov. 13	MT
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024	Nov. 13	BU
Appili Therapeutics Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy	23-10-26	AQ
Appili Therapeutics' Biodefense Vaccine Candidate ATI-1701 Awarded Additional Funding From U.S. Air Force Academy	23-10-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Appili Therapeutics Inc.

Equities

APLI

CA03783R1073

Summary

Filters